Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates for pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.
Company profile
Ticker
RDY
Exchange
Website
CEO
G. Prasad
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
43505116
RDY stock data
News
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
5 Aug 22
India Based Pharma Companies In Race To Buy Athenex, Shares Surge
5 Aug 22
Barclays Maintains Overweight on Dr Reddy's Laboratories, Lowers Price Target to $68
25 Jul 22
Dr. Redy Unit Aurigene Discovery Technologies Limited Announced Drug Discovery, Development and Commercialization Partnership with EQRx
5 Jul 22
Eton Pharma Shares Tick Higher After Offloading Hospital Products
24 Jun 22
Press releases
Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify® in the U.S.
29 Jul 22
Dr. Reddy's Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market
27 Jul 22
Dr. Reddy's Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market
22 Jul 22
Dr. Reddy's Laboratories Announces the Launch of Fesoterodine Fumarate Extended-Release Tablets in the U.S. Market
8 Jul 22
Aurigene Discovery Technologies Limited Announces Drug Discovery, Development and Commercialization Partnership with EQRx
5 Jul 22
Analyst ratings and price targets
Calendar
27 Jun 22
16 Aug 22
31 Mar 23
Financial summary
| Quarter (USD) | Mar 22 | Mar 21 | Mar 20 | Mar 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Mar 22 | Mar 21 | Mar 20 | Mar 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Institutional ownership, Q1 2022
| 13F holders | Current |
|---|---|
| Total holders | 0 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 0 |
| Total shares | 0 |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
8th grade Avg
|
|
New words:
aa, ADC, administeredby, alert, Alium, Allegany, alongside, alsonotify, ALSP, AmeriHealth, Amgen, andcould, anEIR, antigen, Aquestive, arewere, Ashoka, ation, Authorityand, awardsentitl, backward, BDSI, beverage, Beverley, billion, bio, BioDelivery, Boehringer, Bok, bone, broader, BsUFA, cadre, capitaliz, carbon, catastrophic, CCG, CDI, CDMO, ceremony, certainof, Certificado, CFEH, Chemplast, chimeric, CHMP, Ciprolet, Clair, Clayton, Clinton, Cloxacillin, Collector, Combihale, Companyhad, Conceptual, conjugate, conservation, contacted, Cook, Cortland, courtwere, covenant, CTCL, Culverson, Czech, Daffy, Debenture, deferral, degradation, Delhivery, denileukin, Derivativeswhich, detention, diftitox, dimethyl, disregarded, DPAC, ed, eferred, efund, ELYXYB, Entrepreneurship, epreciation, equitable, ertapenem, Eton, faculty, FDAindicating, flat, fo, formula, FPM, Franklin, frequency, Fulton, fusion, gas, gather, geopolitical, greenhouse, ground, Gwendolyn, hare, hasc, headcount, Herkimer, Hong, hypertension, icosapent, ID, IEPF, ignificant, Illustrative, immunology, inducted, indust, infant, Ingelheim, intragroup, irregular, IRS, iteration, itss, JMC, Joseph, JP, JSC, Karnataka, Kong, Krishnan, Kulkarni, laid, lean, Levolet, liberty, Madison, Magnolia, Mangalore, Mankind, manufacturingor, martial, Medac, mental, merged, messenger, Middleburgh, Minister, MOA, Monash, Montgomery, moreperformance, mRNA, NAER, Narasimham, Nassau, NBE, neighboring, NGO, Niagara, nutrition, OAI, odify, ofthe, ompany, oncertain, onset, ontract, Orchid, orindirectly, orrectly, paymentreceived, peak, Penny, piecemeal, pioneer, Portugal, postponed, postponement, PraecipeFor, preclusion, Prime, proper, provisional, PS, pulmonary, receiveda, receptor, recogniz, recourse, Reg, reinforced, relocated, representsthe, resiliency, Rural, ry, safer, samewere, Schenectady, score, secretariat, Shanghai, shortly, Shriram, sizable, Slovakia, spearheaded, Steuben, stronger, subsidiaryAurigene, Sushrut, Sweat, Sweden, Tcell, Temasek, Thai, THB, TheC, thefollowing, theyear, tiered, tighter, tolerability, toxin, unaffected, unfit, uniform, URRA, utiliz, vasopressin, Veraring, viii, Wan, war, Westchester, wholeseller, workplace, Wyeth, xpert, yearsended, Yorkshire, zealously
Removed:
abandon, Abbvie, Addiction, admission, advocacy, Affordability, Allen, anticipation, arisen, Asian, aspect, attaching, attracting, augmenting, avoiding, awaiting, banning, baseline, BBA, Belgium, benchmark, Bennett, Bharat, Biotech, Bipartisan, blocking, bona, Booz, BuFA, Bupa, Cautionary, Chakraborty, chamber, chiral, clarification, clobetasol, clocortolone, Cloderm, closer, Coleman, collaborate, column, comment, comparative, concentrated, coordinate, Dabur, daily, Deccan, declining, deficit, desired, desperately, differentiate, discontinue, diverging, Doshi, Duma, easier, Eicher, eisai, Electric, Eli, emanated, encounter, enjoy, enrolling, entitle, entrenched, EPI, Eurobridge, exclusively, fewer, fide, fluctuation, footprint, formally, fundamental, Ganadhish, gauge, Goa, greatest, grown, Hamilton, harbor, Harvard, Herald, Hospira, HR, hydrochloride, Hydrogen, IMA, immigration, imperative, implanted, Impoyz, inappropriate, inducement, inflationary, influential, infusion, instilled, insufficient, integrating, interact, Intertrade, intranasal, IP, ISPE, ITM, JIBAR, Johannesburg, Kamat, KGaA, landlord, Libre, Lilly, linked, lose, lucrative, Max, Mechanical, Meridian, mini, misuse, Narotam, narrowing, negotiated, netting, Northern, older, OOO, outward, Oxley, parenteral, PDA, Pharmacia, Pharmacopeia, Physiology, Pilani, pivalate, plaque, possessing, potency, PPACA, propionate, publishing, Qualcomm, rand, randomized, Raymond, RCP, reassessed, redefining, referendum, reiterated, reliant, removing, renegotiate, renewable, rental, reprioritization, rich, Salzburg, Saumen, SE, Seminar, serving, specificity, Squibb, Stanford, steroid, stringently, strive, successor, symtouch, systematic, Tecumseh, Tourism, trianex, unchanged, unconstitutional, Universit, unrest, Upjohn, valedictorian, vi, Vr, wage, xenoport, Yugandhar, zonal
Financial reports
Current reports
6-K
Current report (foreign)
8 Aug 22
6-K
Current report (foreign)
3 Aug 22
6-K
Current report (foreign)
1 Aug 22
6-K
Current report (foreign)
1 Aug 22
6-K
Current report (foreign)
1 Aug 22
6-K
Current report (foreign)
28 Jul 22
6-K
Dr. Reddy’s Q1 FY23 Financial Results
28 Jul 22
6-K
Report of Independent Registered Public Accounting Firm
28 Jul 22
6-K
Current report (foreign)
27 Jul 22
6-K
Current report (foreign)
22 Jul 22
Registration and prospectus
S-8
Registration of securities for employees
4 Sep 18
S-8
Registration of securities for employees
4 Mar 07
424B3
Prospectus supplement
16 Nov 06
424B3
Prospectus supplement
12 Nov 06
F-3ASR
Automatic shelf registration (foreign)
12 Nov 06
F-6EF
Automatic registration for ADRs (foreign)
8 Nov 06
S-8
Registration of securities for employees
1 Dec 03
S-8
Registration of securities for employees
30 Oct 02
Proxies
No filings
Other
CT ORDER
Confidential treatment order
2 Aug 17
UPLOAD
Letter from SEC
16 Feb 15
CORRESP
Correspondence with SEC
11 Feb 15
UPLOAD
Letter from SEC
29 Jan 15
UPLOAD
Letter from SEC
9 Apr 14
CORRESP
Correspondence with SEC
2 Apr 14
CORRESP
Correspondence with SEC
2 Apr 14
UPLOAD
Letter from SEC
19 Mar 14
UPLOAD
Letter from SEC
30 May 13
CORRESP
Correspondence with SEC
5 May 13
Ownership
SC 13D/A
DR REDDYS LABORATORIES / Dr. Reddy's ownership change
2 May 22
SC 13G/A
DR REDDYS LABORATORIES / MITSUBISHI UFJ FINANCIAL ownership change
2 Feb 21
SC 13G/A
DR REDDYS LABORATORIES / BlackRock ownership change
9 Apr 20
SC 13G
Beneficial ownership report
13 Feb 20
SC 13G
Beneficial ownership report
7 Feb 20
SC 13G/A
Beneficial ownership report (amended)
10 Dec 19
SC 13G
DR Reddys Laboratories LTD
9 Sep 19
SC 13G
Beneficial ownership report
7 Feb 19
SC 13G
DR Reddys Laboratories LTD
17 Jan 19
SC 13G
DR Reddys Laboratories LTD
12 Feb 18
Patents
Utility
Pharmaceutical compositions for N-propargylamine derivative
23 Nov 20
The present application relates to a method of treating Parkinson's disease by administering a mouth-dissolving composition of N-propargylamine derivative, such as rasagiline or a pharmaceutically-acceptable salt thereof.
Utility
Oral Composition of Celecoxib for Treatment of Pain
11 Nov 20
The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or pharmaceutically acceptable salts thereof.
Utility
Oral composition of celecoxib for treatment of pain
12 Oct 20
The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or its pharmaceutically acceptable salts thereof.
Transcripts
2023 Q1
Earnings call transcript
31 Jul 22
2022 Q4
Earnings call transcript
19 May 22
2022 Q3
Earnings call transcript
28 Jan 22
2021 Q1
Earnings call transcript
27 Jul 21
2021 Q4
Earnings call transcript
14 May 21
2021 Q3
Earnings call transcript
30 Jan 21
2021 Q2
Earnings call transcript
28 Oct 20
Reddit threads
Daily Discussion Thread - August 1st, 2022
1 Aug 22
Daily Discussion Thread - July 26th, 2022
26 Jul 22
Daily Discussion Thread - July 25th, 2022
25 Jul 22
Daily Discussion Thread - July 8th, 2022
8 Jul 22
Daily Discussion Thread - July 7th, 2022
7 Jul 22
Daily Discussion Thread - July 6th, 2022
6 Jul 22
Daily Discussion Thread - July 5th, 2022
5 Jul 22
Daily Discussion - Friday June 24 2022
24 Jun 22
Daily Discussion Thread - May 20th, 2022
20 May 22
Daily Discussion Thread - May 19th, 2022
19 May 22